Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

Ajai Chari, Hareth Nahi, Maria-Victoria Mateos, MD, Henk M. Lokhorst, Jonathan L. Kaufman, MD, Philippe Moreau, MDPhD, Albert Oriol, MD, Torben Plesner, MD, Lotfi Benboubker, MD, Peter Hellemans, Tara Masterson, Pamela L Clemens, Kevin Liu, Jesus F. San-Miguel, MD, Saad Z Usmani, MD

Blood (2017) 130 (Supplement 1): 838.

https://doi.org/10.1182/blood.V130.Suppl_1.838.838

Published: 2017

Journal Articles

Genomic Predictors of Progression-Free Survival Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial

Robert J Pelham, PhD, Xuguang Hu, PhD, Philippe Moreau, MDPhD, Albert Oriol, MD, Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Tibor Kovacsovics, Jonathan J Keats, PhD, Shibao Feng, PhD, Amy S. Kimball, Meletios A. Dimopoulos

Blood (2017) 130 (Supplement 1): 839.

https://doi.org/10.1182/blood.V130.Suppl_1.839.839

Published: 2017

Journal Articles

The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow

Davine Hofste Op Bruinink, MD, Vincent van der Velden, PhD, Mark van Duin, PhD, Berna Beverloo, PhD, Jeroen te Marvelde, BSc, Chelsea den Hollander, BSc, Rowan Kuiper, MSc, Michel Delforge, MDPhD, Martin H van Vliet, PhD, Niels WCJ van de Donk, MDPhD, Hervé Avet-Loiseau, MDPhD, Philippe Moreau, MDPhD, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 4368.

https://doi.org/10.1182/blood.V130.Suppl_1.4368.4368

Published: 2017

Journal Articles

The Use of a BH3 Mimetic Toolkit Reveals a Switch of Myeloma Patients Dependency from BCL2 at Diagnosis to MCL1 at Relapse

Antoine Bonnet, MD, Jessie Bourcier, MD, Patricia Gomez-Bougie, PhD, Sophie Maïga, Benoit Tessoulin, MD, Philippe Moreau, MDPhD, Steven Le Gouill, MDPhD, Catherine Pellat-Deceunynck, PhD, Cyrille Touzeau, MD PhD, Martine Amiot, PhD

Blood (2017) 130 (Supplement 1): 4383.

https://doi.org/10.1182/blood.V130.Suppl_1.4383.4383

Published: 2017

Journal Articles

Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study

Sagar Lonial, MD, Jesus F. San-Miguel, MD, Joaquín Martínez-Lopez, Maria-Victoria Mateos, MD, Joan Blade, Lotfi Benboubker, MD, Albert Oriol, MD, Bertrand Arnulf, Ajai Chari, Luis Pineiro, Kaida Wu, Jianping Wang, Parul Doshi, Jordan Schecter, Philippe Moreau, MDPhD

Blood (2017) 130 (Supplement 1): 1869.

https://doi.org/10.1182/blood.V130.Suppl_1.1869.1869

Published: 2017

Journal Articles

Clofarabine-Based Reduced Intensity Conditioning Regimen with Post-Transplant Cyclophosphamide and Peripheral Stem Cell Graft in Adults with Myeloid Malignancies: Results of the Clo-Baltimore Regimen

Patrice Chevallier, MD, Pierre Peterlin, MD, Alice Garnier, MD, Amandine Le Bourgeois, PhD, Beatrice Mahe, MD, Viviane Dubruille, MD, Nicolas Blin, Pierre Gallas, MD, Cyrille Touzeau, MD PhD, Thomas Gastinne, MD, Anne Lok, MD, Yannick LE Bris, MDPharmD, Marie C Bene, PharmD,DPhil, Hugo Charles, Steven Le Gouill, MDPhD, Philippe Moreau, MDPhD, Thierry Guillaume, MD PhD

Blood (2017) 130 (Supplement 1): 1964.

https://doi.org/10.1182/blood.V130.Suppl_1.1964.1964

Published: 2017

Journal Articles

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux

Philippe Moreau, MDPhD, Albert Oriol, MD, Jonathan L. Kaufman, MD, Heather Sutherland, MD, Marc Lalancette, MD FRCP, Hila Magen, MD, Shinsuke Iida, MD PhD, Jin Seok Kim, MD PhD, Miles Prince, MD FRACP, FRCPA, Tara Cochrane, Lisa O'Rourke, MSN, RN, Kaida Wu, Jordan M. Schecter, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 1883.

https://doi.org/10.1182/blood.V130.Suppl_1.1883.1883

Published: 2017

Journal Articles

Mixed Chimerism of Bone Marrow CD34+ Sorted Cells after Matched or Haploidentical Allogeneic Stem Cell Transplantation for Myeloid Malignancies Is Predictive of Relapse

Yannick LE Bris, MDPharmD, Audrey Menard, Thierry Guillaume, MD PhD, Pierre Peterlin, MD, Alice Garnier, MD, Amandine Le Bourgeois, PhD, Philippe Moreau, MDPhD, Mohamad Mohty, MD PhD, Marie C Bene, PharmD,DPhil, Patrice Chevallier, MD

Blood (2017) 130 (Supplement 1): 1930.

https://doi.org/10.1182/blood.V130.Suppl_1.1930.1930

Published: 2017

Journal Articles

Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance Is a Safe and Effective Strategy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM)

Philippe Moreau, MDPhD, Cyrille Hulin, MD, Denis Caillot, MD, Gerald Marit, MD, Aurore Perrot, MD, Laurent Garderet, MD PhD, Thierry Facon, MD, Lofti Benboubker, MD, Lionel Karlin, MD, Mourad Tiab, Bertrand Arnulf, MD PhD, Xavier Leleu, MD PhD, Cyrille Touzeau, MD PhD, Murielle Roussel, Lucie Planche, Hervé Avet-Loiseau, Thomas Dejoie, Michel Attal, MD PhD

Blood (2017) 130 (Supplement 1): 2021.

https://doi.org/10.1182/blood.V130.Suppl_1.2021.2021

Published: 2017

Journal Articles

Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)

Blood (2017) 130 (Supplement 1): 398.

https://doi.org/10.1182/blood.V130.Suppl_1.398.398

Published: 2017

Journal Articles

Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial

Hervé Avet-Loiseau, MD PhD, Valerie Lauwers-Cances, MD, Jill Corre, PharmD, PhD, Philippe Moreau, MDPhD, Michel Attal, MD PhD, Nikhil Munshi, MD

Blood (2017) 130 (Supplement 1): 435.

https://doi.org/10.1182/blood.V130.Suppl_1.435.435

Published: 2017

Journal Articles

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux

Meletios A. Dimopoulos, Darrell J. White, MD, Lofti Benboubker, MD, Gordon Cook, MD PhD, Merav Leiba, James Morton, P. Joy Ho, MBBS, DPhil, FRACP, FRCPA, FFSc(RCPA), Kihyun Kim, Naoki Takezako, MD PhD, Sonali Trivedi, Kaida Wu, Tineke Casneuf, Christopher Chiu, Jordan Schecter, Philippe Moreau, MDPhD

Blood (2017) 130 (Supplement 1): 739.

https://doi.org/10.1182/blood.V130.Suppl_1.739.739

Published: 2017

Journal Articles

A Multicenter Open Label Phase II Study of Pomalidomide, Cyclophosphamide and Dexamethasone in Relapse Multiple Myeloma Patients Initially Treated with Lenalidomide, Bortezomib and Dexamethasone

Blood (2017) 130 (Supplement 1): 837.

https://doi.org/10.1182/blood.V130.Suppl_1.837.837

Published: 2017

Journal Articles

Subcutaneous Rituximab Given to Patients for Other Indications Than CD20+ B-Cell Lymphoma: A Monocentric Study of 20 Cases

Pierre Peterlin, MD, Thierry Guillaume, MD PhD, Alice Garnier, MD, Amandine Le Bourgeois, PhD, Beatrice Mahe, MD, Viviane Dubruille, MD, Nicolas Blin, MD, Pierre Gallas, MD, Cyrille Touzeau, MD PhD, Thomas Gastinne, MD, Anne Lok, MD, Patrick Thomaré, PharmSciD, Cécile Chauvin, PharmSciD, Steven Le Gouill, MD PhD, Philippe Moreau, MDPhD, Patrice Chevallier, MD PhD

Blood (2017) 130 (Supplement 1): 5477.

https://doi.org/10.1182/blood.V130.Suppl_1.5477.5477

Published: 2017

Journal Articles

Elevated Cardiovascular Risk Factors at Time of Allotransplant Do Not Impact Survivals in Adult Patients: A Retrospective Study of 194 Cases

Sophie Vantyghem, Thierry Guillaume, MD PhD, Pierre Peterlin, MD, Alice Garnier, MD, Amandine Le Bourgeois, PhD, Beatrice Mahe, MD, Viviane Dubruille, MD, Nicolas Blin, Pierre Gallas, MD, Cyrille Touzeau, MD PhD, Thomas Gastinne, MD, Anne Lok, MD, Steven Le Gouill, MDPhD, Philippe Moreau, MDPhD, Marie C Bene, PharmD,DPhil, Patrice Chevallier, MD

Blood (2017) 130 (Supplement 1): 5533.

https://doi.org/10.1182/blood.V130.Suppl_1.5533.5533

Published: 2017

Journal Articles

The Genomic Landscape of Multiple Myeloma Complex Structural Variations

Blood (2017) 130 (Supplement 1): 330.

https://doi.org/10.1182/blood.V130.Suppl_1.330.330

Published: 2017

Journal Articles

Impact of Early Post-Transplant 5-Point Deauville Scale (18)F-FDG-PET Status on Survival Outcomes after Allogeneic Transplantation for Lymphoma

Louise Bouard, Caroline Bodet-Milin, Thierry Guillaume, MD PhD, Pierre Peterlin, MD, Clement Bailly, Alice Garnier, MD, Amandine Le Bourgeois, PhD, Beatrice Mahe, MD, Viviane Dubruille, MD, Nicolas Blin, Pierre Gallas, MD, Cyrille Touzeau, MD PhD, Thomas Gastinne, MD, Anne Lok, MD, Lucie Planche, Steven Le Gouill, MDPhD, Philippe Moreau, MDPhD, Francoise Kraeber-Bodere, Patrice Chevallier, MD

Blood (2017) 130 (Supplement 1): 3266.

https://doi.org/10.1182/blood.V130.Suppl_1.3266.3266

Published: 2017

Journal Articles

Clonality Analysis Reveals the Order of Acquisition of Copy Number Alterations in Multiple Myeloma

Anil Aktas Samur, PhD, Mehmet Kemal Samur, PhD, Stephane Minvielle, Florence Magrangeas, Yu-Tzu Tai, PhD, Mariateresa Fulciniti, PhD, Paul G Richardson, MD, Philippe Moreau, MDPhD, Kenneth C Anderson, MD, Michel Attal, MD PhD, Hervé Avet-Loiseau, Nikhil Munshi, MD

Blood (2017) 130 (Supplement 1): 1773.

https://doi.org/10.1182/blood.V130.Suppl_1.1773.1773

Published: 2017

Journal Articles

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study

Torben Plesner, MD, Hendrik-Tobias Arkenau, Francesca Marianatal Gay, Monique C Minnema, Mario Boccadoro, Philippe Moreau, MDPhD, James D Cavenagh, Aurore Perrot, MD, Jacob Laubach, MD, Tahamtan Ahmadi, Carla de Boer, Diana Chen, Christopher Chiu, Jordan Schecter, Paul G Richardson, MD

Blood (2017) 130 (Supplement 1): 1828.

https://doi.org/10.1182/blood.V130.Suppl_1.1828.1828

Published: 2017

Journal Articles

Time to Improve Bortezomib and Lenalidomide Lines of Therapy

Blood (2017) 130 (Supplement 1): 1853.

https://doi.org/10.1182/blood.V130.Suppl_1.1853.1853

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

Genomic Predictors of Progression-Free Survival Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial

The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow

The Use of a BH3 Mimetic Toolkit Reveals a Switch of Myeloma Patients Dependency from BCL2 at Diagnosis to MCL1 at Relapse

Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study

Clofarabine-Based Reduced Intensity Conditioning Regimen with Post-Transplant Cyclophosphamide and Peripheral Stem Cell Graft in Adults with Myeloid Malignancies: Results of the Clo-Baltimore Regimen

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux

Mixed Chimerism of Bone Marrow CD34+ Sorted Cells after Matched or Haploidentical Allogeneic Stem Cell Transplantation for Myeloid Malignancies Is Predictive of Relapse

Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)

Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux

A Multicenter Open Label Phase II Study of Pomalidomide, Cyclophosphamide and Dexamethasone in Relapse Multiple Myeloma Patients Initially Treated with Lenalidomide, Bortezomib and Dexamethasone

Subcutaneous Rituximab Given to Patients for Other Indications Than CD20+ B-Cell Lymphoma: A Monocentric Study of 20 Cases

Elevated Cardiovascular Risk Factors at Time of Allotransplant Do Not Impact Survivals in Adult Patients: A Retrospective Study of 194 Cases

The Genomic Landscape of Multiple Myeloma Complex Structural Variations

Impact of Early Post-Transplant 5-Point Deauville Scale (18)F-FDG-PET Status on Survival Outcomes after Allogeneic Transplantation for Lymphoma

Clonality Analysis Reveals the Order of Acquisition of Copy Number Alterations in Multiple Myeloma

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study

Time to Improve Bortezomib and Lenalidomide Lines of Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only